Angioplasty Balloons Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Angioplasty Balloons Market Trends and Insights

Rising Cardiovascular Disease Prevalence

The number of adults living with clinical cardiovascular disease is projected to top 45 million in the United States alone by 2050. Hypertension, diabetes, and obesity rates all continue to climb, reinforcing a long-run need for catheter-based revascularization. Although coronary mortality dropped markedly between 2000 and 2020, it has plateaued in recent years, keeping demand for balloon angioplasty stable. Hospitalizations linked to heart disease cost USD 108 billion in 2021, and forecasts point to USD 131.3 billion by 2030, highlighting the economic imperative for cost-effective minimally invasive solutions^{[1]American Heart Association, “Heart Disease and Stroke Statistics 2025 Update,” heart.org}.

Shift toward Minimally-invasive PCI & Technology Advances

Clinical practice now favors percutaneous catheter approaches that shorten recovery and curb facility costs. Standardized endpoints for coronary DCB trials released in 2025 have legitimized drug-coated balloons, which posted 17.9% target-lesion failure at 1 year versus 28.6% with plain balloons. Intravascular lithotripsy is gaining momentum, using acoustic pressure waves inside the balloon to fracture calcium and improve luminal gain. These technologies collectively strengthen the angioplasty balloons market outlook by enhancing outcomes without leaving permanent metal behind^{[2]Boston Scientific, “AGENT IDE Trial Results,” bostonscientific.com}.

Expanding Geriatric PAD Pool in Emerging Economies

Peripheral artery disease (PAD) incidence is climbing sharply in many Asian and Latin American populations as life expectancy rises and Western lifestyle risk factors spread. Longer balloon lengths, dedicated drug coatings, and deliverability improvements have made femoropopliteal and below-the-knee interventions more practical in resource-constrained settings. Five-year data from the IN.PACT Global Study showed 69.4% freedom from clinically driven target-lesion revascularization for DCBs in femoropopliteal disease, bolstering adoption in these high-volume markets.

Breakthroughs in Bio-resorbable & Ultra-high-pressure Polymers

Material science continues to redefine performance. Abbott’s Esprit BTK Everolimus-Eluting Resorbable Scaffold gained FDA approval in 2024, demonstrating a viable dissolving device for critical limb ischemia. Separately, ultra-high-pressure balloons such as OPN NC now withstand inflation pressures above 40 atm, enabling treatment of heavily calcified lesions that once required surgery. Drug-delivery innovations, including nano-encapsulated sirolimus, promise safer and more durable antirestenotic effects^{[3]Abbott Laboratories, “Esprit BTK Resorbable Scaffold System Receives FDA Approval,” abbott.com}.

High Procedure & Device Cost versus Stenting Bundles

Healthcare payers remain cautious when balloon-only strategies appear more expensive than bundled stent packages that include follow-up imaging and medication plans. Despite Medicare approval, ASCs still perform only 1.8% of outpatient PCIs in the United States, signaling persistent economic hesitation. Premium pricing on drug-coated balloons tightens purchasing decisions, especially where supply-chain inflation has lifted input costs to 20% of device revenues.

Regulatory Scrutiny on Paclitaxel DCB Safety Signals

Although the FDA lifted restrictions, lingering concern regarding late mortality in paclitaxel-based DCBs slows adoption. Labels for leading paclitaxel platforms include explicit warnings mandating patient discussions, and post-market surveillance obligations raise compliance costs. These uncertainties are driving interest in sirolimus-coated alternatives and in next-generation trial designs that more clearly delineate mortality risk^{[4]U.S. Food & Drug Administration, “Premarket Approval AGENT Drug-Coated Balloon,” fda.gov}.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Product Type: Scoring Balloons Drive Specialized Growth

Scoring balloons held the fastest growth trajectory at 4.26% CAGR through 2031, a pace that reflects their role in plaque-modification strategies for calcified or fibrotic lesions. The angioplasty balloons market size for scoring systems is rising as studies such as Naviscore’s first-in-man series reported 94% procedural success in moderate-to-severe calcification. Normal balloons still dominate everyday PCI with 41.02% 2025 share because they remain indispensable for routine pre- and post-dilation steps.

Drug-coated balloons gained decisive momentum after Boston Scientific’s AGENT approval, which showed a 50% reduction in repeat revascularization compared with conventional angioplasty. Cutting balloons preserve a niche for in-stent restenosis and small-vessel work, with meta-analysis indicating a 33% reduction in target-lesion revascularization risk. Ultra-high-pressure variants, now exceeding 40 atm, extend percutaneous treatment to hard fibro-calcific plaques, expanding the angioplasty balloons market both procedurally and technologically.

By Application: Peripheral Angioplasty Accelerates Growth

Peripheral interventions are forecast to post 4.05% CAGR to 2031, reflecting surging PAD prevalence amid aging demographics and lifestyle changes. Freedom-from-revascularization rates of 69.4% at 5 years for drug-coated balloons validate durability in the femoropopliteal segment, anchoring demand outside the coronary arena. Coronary angioplasty still delivered 56.30% of 2025 revenue and remains the most common procedure; however, secondary prevention initiatives and optimized medical therapy cap its growth.

Emerging tools, including dissolving scaffolds for below-the-knee disease, further broaden therapeutic reach. Intravascular lithotripsy integration with long peripheral balloons improves luminal expansion in diffuse calcified lesions. The peripheral trend diversifies the angioplasty balloons market, helping balance plateauing coronary volumes and giving manufacturers new avenues for innovation.

By End User: Ambulatory Centers Reshape Care Delivery

Hospitals retained 70.65% of global revenue in 2025 because of comprehensive cardiac services and readiness for complex or emergent cases. Still, the angioplasty balloons market is experiencing a pronounced site-of-care shift. Ambulatory surgical centers are on a 4.58% CAGR trajectory through 2031 because Medicare now reimburses PCI outside hospital walls. Recent claims data confirm that ASC PCI volume, while still small, is accelerating quickly.

Cost efficiency and patient-experience gains serve as key ASC advantages, although stringent patient-selection protocols remain essential. New ASC-only C codes for diagnostic catheterization and PCI elevate reimbursement predictability, nudging cardiology groups to develop freestanding labs. Quality-outcome benchmarks and standardized discharge criteria will further support outpatient expansion, sustaining angioplasty balloons market growth in this setting.

Geography Analysis

North America led with 39.25% angioplasty balloons market share in 2025, supported by broad insurance coverage, established cath-lab networks, and early adoption of premium devices. The region’s regulatory environment favors innovation, evidenced by the 2024 clearance of the AGENT coronary DCB. CMS policy changes permitting ASC-based PCI have begun to reshape volume distribution, yet hospitals keep the bulk of complex procedures. Persistent supply-chain turbulence has forced local manufacturers to absorb double-digit logistics and raw-material inflation, heightening focus on digital inventory control. Consolidation remained active, highlighted by Teleflex’s EUR 760 million acquisition of BIOTRONIK’s vascular unit, which enriched its drug-coated balloon and stent offerings.

Asia-Pacific registers the swiftest expansion at 4.45% CAGR. Population aging, urbanization, and infrastructure build-out are unlocking cath-lab demand. Government moves to harmonize device approvals and encourage domestic manufacturing continue to reduce time-to-market for new balloons. Regional clinical guidelines now recommend DCBs for small-vessel disease and in-stent restenosis, aligning therapy choices with global standards. Growth, however, is tempered by price sensitivity, which pushes buyers toward cost-effective platforms and accelerates local production of basic balloons even as demand for high-end scoring and drug-coated variants climbs.

Europe delivers steady but measured gains as economic pressures constrain premium device uptake in some public-health systems. The Medical Device Regulation (MDR) framework, while rigorous, provides clarity that helped Terumo secure CE marks for several vascular-closure solutions in 2024, sustaining procedural ecosystems. Cordis’s SELUTION SLR sirolimus-eluting balloon posted 81.5% three-year patency in Japan and 91.1% freedom from target-lesion revascularization in European trials, reinforcing drug-coated platforms. Clinical collaboration through groups such as the Drug-Coated Balloon Academic Research Consortium promotes evidence-based adoption across the continent, maintaining Europe’s role as a bellwether market for next-generation balloons.

Regulatory Landscape

Angioplasty balloons are regulated as medical devices in most jurisdictions, while drug-coated balloons (DCBs) add drug-device combination requirements that raise clinical and quality thresholds. In the United States, the FDA product classification for percutaneous transluminal coronary angioplasty (PTCA) balloon catheters and DCBs drives premarket expectations, and combination-product manufacturers must comply with 21 CFR Part 4, aligning device QSR with drug CGMP controls. FDA also maintains active safety communications for paclitaxel-coated balloons and stents used in peripheral arterial disease, keeping labeling, physician-patient discussion, and post-market monitoring central for paclitaxel DCB platforms.

In Europe, Regulation (EU) 2017/745 (MDR) governs device approval and ongoing compliance. Drug-eluting balloons require robust clinical evaluation (including CER expectations under Annex XIV) and notified-body oversight. Consensus standards and test methods shape submissions and comparability, including FDA-recognized coating characterization for DCBs (ASTM F3320-18) and international standards such as ISO 12417-1:2024 for cardiovascular vascular device-drug combination products. This standards-driven environment increases the burden of demonstrating coating integrity, drug dose uniformity, and manufacturing change control across regions.

Value Chain Analysis

The angioplasty balloon value chain starts with upstream inputs, including medical-grade polymers (such as nylon and PET used for balloon and catheter components), radiopaque markers, and specialty hypotube or shaft materials. For drug-coated balloons, the chain expands to include GMP-grade active pharmaceutical ingredients (commonly paclitaxel or emerging sirolimus approaches) and excipients, as well as proprietary coating consumables and process know-how. Core manufacturing spans extrusion and balloon forming, surface preparation, coating application with controlled drug or excipient ratios, and drying or curing, followed by catheter assembly and packaging. Terminal sterilization, often ethylene oxide, and final release testing complete the manufacturing flow.

Downstream, products move through OEM direct sales and distributors to hospitals and ambulatory surgical centers, with procedure adoption influenced by clinical evidence and reimbursement policies. Key friction points include constrained availability of validated EtO sterilization capacity, limited sources of GMP-certified drug substance for DCBs, and the need to revalidate coating performance when suppliers or processes change. These constraints increase the strategic value of vertical integration and supplier qualification, particularly for DCB platforms where coating uniformity and change control can affect regulatory timelines and continuity of supply.

Market Opportunities and Future Outlook

Technology whitespace is opening around non-paclitaxel drug delivery and longer-term durability signals, supported by clinical and regulatory sensitivity to paclitaxel risk-benefit communication. In 2026, multiple sirolimus-coated balloon data disclosures, including Concept Medical presentations for MagicTouch in peripheral artery disease and longer-term comparative durability readouts, along with Cordis commercial action (SELUTION SLR PTA launch in Japan supported by multi-year patency data), point to active momentum behind sirolimus approaches across peripheral interventions. This creates room for suppliers with scalable coating processes, repeatable drug-dose uniformity, and clinical programs that demonstrate low reintervention rates in complex PAD segments.

Operationally, manufacturing change control and supply resilience remain actionable opportunity areas, since DCBs depend on qualified drug supply, coating process stability, and validated sterilization capacity. Recent FDA-reviewed manufacturing updates, including site and supplier changes recorded through PMA supplements, show that supply chain decisions are increasingly tied to regulatory maintenance as well as cost. Companies that can regionalize production, qualify alternate critical suppliers without performance drift, and support outpatient site-of-care shifts with consistent availability and training can compete more effectively as procedure settings diversify.